Missing Data

A PSI Training Course on Missing Data

Presented by Mike Kenward (GlaxoSmithKline Professor of Biostatistics) and James Roger  (Honorary Professor of Biostatistics) Department of Medical Statistics
London School of Hygiene and Tropical Medicine

There has been much recent activity concerning the problem of handling missing data in clinical trials. In 2010, a new set of guidelines was produced by the European regulators, and a major report was produced by the US National Research Council Panel on Handling Missing Data in Clinical Trials, at the behest of the FDA. The current course has two main threads that reflect this activity. In the first, the conceptual issues surrounding missing data in clinical trials are explored, reflecting the debate that has been taking place over the last ten years. In the second, the relevant statistical methodology is introduced and developed In particular there will be an introduction to the roles of the so-called selection and pattern-mixture frameworks, and to multiple imputation. For completeness and for purposes of comparison there will also be a brief treatment of other approaches, including ad hoc methods such as Last Observation Carried Forward (LOCF) and more principled approaches like inverse probability weighting. The two main threads will be brought together in a thorough exploration of sensitivity analyses that can be applied in this setting. Methodology will be illustrated with examples from real longitudinal clinical trials, using SAS procedures and macros. The course will consist of lectures. There will not be any computer exercises.

The following key topics will be addressed:
• The documents from US and European regulators.
• Definitions: missing value mechanisms (MCAR, MAR, MNAR), ignorability, estimands (de jure, de facto); other jargon: intention to treat, per protocol, efficacy, effectiveness.
• The distinction between missingness as a nuisance and as part of the outcome.
• Ad hoc methods: completers analyses, last observation carried forward, simple imputation, worst case analyses.
• Model based analyses under MAR for continuous and categorical data.
• Sensitivity analyses: selection and pattern-mixture models, multiple imputation, controlled imputation
 
Use of Computers:

There will not be any workshops where course participants do their own computing, but there will be extensive examples throughout the course, and example code will be supplied showing how to implement the preferred methods. All such code is either in the public domain or is made freely available to the participants for them to copy and use within their own organisations.

About the presenters:

Mike Kenward, GSK Professor of Biostatistics, Department of Medical Statistics, London School of Hygiene and Tropical Medicine

Mike Kenward has worked in Iceland, Finland and the UK, in both research institutes and universities.  He has a broad interest in modelling in biostatistics, with particular experience in longitudinal data and cross-over trials, as well as the general problem of missing data. He has co-authored three textbooks, The Design and Analysis of Cross-Over Trials (with Byron Jones), Missing Data in Clinical Studies (with Geert Molenberghs) and Multiple Imputation and its Application (with James Carpenter). He has been a consultant, principally for the pharmaceutical industry, for over 25 years, and has given many short courses throughout the world on various areas of biostatistics, especially missing data.

James Roger, Honorary Professor of Biostatistics,  Department of Medical Statistics, London School of Hygiene and Tropical Medicine

James Roger has a long career as university lecturer and statistician within with pharmaceutical industry including periods with J&J and GSK. Collaboration with Mike Kenward has spanned most of that career. James’ interest in missing data stemmed from shared research on linear mixed models and small sample approximations. Recent collaboration has centred on methods that address alternative estimands to those associated with classic MAR. Collaboration with GSK has allowed the development of an implementation of these approaches within SAS using multiple imputation.

Course runs from:  10:00 – 17:30 (registration from 9:30) on Day 1 and 09:00 – 16:00 on Day 2.

Registration
Please register online at www.psiweb.org and click on Events; payment now available online.
Registration costs (includes lunch and refreshments)

Registration before 15 April 2014
PSI Members: £495 plus vat
Non-members: £540 plus vat 

Registration on or after 15 April 2014
PSI Members: £595 plus vat
Non-members: £640 plus vat
Accommodation can’t be guaranteed after the early bird deadline

PSI aims to be fully inclusive and endeavours to accommodate delegates with disabilities wherever possible.  Please help us to help you by letting us know if you require additional facilities or have any special requirements.  Please contact us on +44 (0)845 1800 349 or at PSI@mci-group.com for further information.

Contact: Emma Lovett,  Tel:  +44 (0)845 1800 349    Email: PSI@mci-group.com

EventsFuture Events


  • Statisticians in the Age of AI: On Route to Strategic Partnership - Dates: 24 – 24 Mar, 2026

    A 90-minute webinar featuring two case studies from Bayer and Roche demonstrating how statisticians successfully integrated into AI programs, followed by interactive discussion on strategies for elevating statistical expertise in the AI era.
  • Strategic role of statisticians for JCA - Dates: 24 – 24 Mar, 2026

    Join our Health Technology Assessment (HTA) European Special Interest Group (ESIG) for a webinar on the strategic role of statisticians in the Joint Clinical Assessment (JCA). The introduction of the JCA marks a new era for evidence generation and market access in Europe. As HTA requirements become more harmonized and methodologically demanding, the role of statisticians has evolved far beyond data analysis. Today, statistical expertise is central to shaping clinical development strategies, designing robust comparative evidence, and ensuring that submissions withstand the scrutiny of EU-level assessors. In this webinar, we explore how statisticians contribute strategically to successful JCA outcomes.
PIERRE_FABRE_LOGOTYPE_RVB

Pierre Fabre - Lead Statistician – Real World Evidence -CDI- M/F

read more...

PIERRE_FABRE_LOGOTYPE_RVB

Pierre Fabre - Clinical Development Safety Statistics Expert M/F

read more...

PIERRE_FABRE_LOGOTYPE_RVB

Pierre Fabre - Lead Statistician- Clinical Trials M/F

read more...

novartis

Novartis - Principal Statistical Programmer

read more...

novartis

Novartis - Senior Principal Statistical Programmer

read more...

novartis

Novartis - Associate Director, Statistical Programming

read more...

gsk logo

GSK - Statistics Director - Vaccines and Infectious Disease

read more...

veramed logo

Veramed - Senior or Principal Statistician - UK/EU (Remote/ Hybrid/ Office)

read more...

novartis

Novartis - Associate Director Biostatistics

read more...

novartis

Novartis - Senior Principal Biostatistician

read more...

plusproject

Plus-Project - Senior Statistician

read more...

ICLR-7ab8d323

ICON PLC - Principal Biostatistician

read more...

ICLR-7ab8d323

ICON PLC - Statistical Scientist

read more...

ICLR-7ab8d323

ICON PLC - Senior Biostatistician

read more...

ICLR-7ab8d323

ICON PLC - Biostatistician II

read more...

ICLR-7ab8d323

ICON PLC - Pharmacometrician

read more...

veramed logo

Veramed - Senior Statistical Programmer

read more...